C
Cephagenix
The startup develops targeted migraine treatments by creating selective inhibitors of the adenosine triphosphate-sensitive potassium channel subtype found in intracranial arteries. These compounds have shown efficacy in preclinical models, providing a mechanism-based approach to alleviate migraine symptoms for affected individuals.
Traction –/10
Glostrup, Denmark · HQ
- Biotechnology
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops targeted migraine treatments by creating selective inhibitors of the adenosine triphosphate-sensitive potassium channel subtype found in intracranial arteries. These compounds have shown efficacy in preclinical models, providing a mechanism-based approach to alleviate migraine symptoms for affected individuals.